通过p66Shc向机制预防高血压诱导的血管功能障碍
Bradley Miller1, John D Imig2,3, Mengjie Li4
1Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, United States.
American journal of physiology. Renal physiology
|April 2, 2025
概括
硫异二胺A2 (SHetA2) 恢复脏微血管反应能力,并减轻高血压诱导脏病的脏损伤. 这种针对p66Shc的化合物显示出治疗高血压相关损伤的前景.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 高血压诱导的脏病 (HN) 通常会导致脏微血管损伤.
- 过度表达p66Shc适应蛋白导致HN中脏微血管反应能力受损.
- 硫异氨酸A2 (SHetA2) 是已知的p66Shc信号传输的调节器.
研究的目的:
- 调查SHetA2在恢复脏微血管活性和减轻脏损伤中的治疗潜力,在HN的小鼠模型中.
- 为了确定SHetA2是否可以防止与高血压相关的功能下降.
主要方法:
- 在一个成熟的HN模型中利用了对达尔盐敏感 (SS) 和p66Shc淘汰 (p66Shc-KO) 的大鼠.
- 在HN发育过程中,急性地给分离的 afferent arterioles 和慢性地给大鼠施用SHetA2.
- 使用 perfused juxtamedullary nephron 制剂评估了的微血管反应性.
- 通过尿路蛋白质分泌和球损伤分析评估损伤.
主要成果:
- 在SS大鼠中,SHetA2显示了微血管反应的剂量依赖性恢复,在p66Shc-KO大鼠中影响最小.
- 慢性SHetA2治疗保留了脏微血管反应,并防止了功能下降.
- 与雌性相比,SHetA2在雄性大鼠中表现出更大的强度和有效性.
结论:
- 用SHetA2准p66Shc有效地减少高血压引起的损伤,并恢复 afferent动脉的反应性.
- SHetA2显示出预防和治疗高血压引起的损伤的巨大潜力.
- 这些发现支持进一步临床转化SHetA2用于管理HN.
相关概念视频
01:18Hypertension and Regulation of Blood Pressure
1.8K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
1.8K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
456
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
456
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
331
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
331
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
406
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
406
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
414
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
414
01:23Antihypertensive Drugs: Vasodilators
440
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
440